Senseonics Holdings, Inc. (NYSE:SENS), a leading diabetes management company, witnessed a significant surge in its stock price, soaring 5.44% in the pre-market trading session on Monday. This rally in Senseonics' shares can be attributed to the company's recent success with its flagship product, Eversense 365, and its ambitious growth plans for the upcoming year.
In the third quarter of 2024, Senseonics achieved a major milestone by obtaining FDA approval and launching Eversense 365, the world's first 365-day continuous glucose monitoring (CGM) system. This groundbreaking product garnered remarkable success, with the company reporting increased patient shipments, a rise in prescribing providers, and a significant surge in prescriptions from top prescribers.
Building on this momentum, Senseonics has set ambitious goals for 2024. The company plans to double its patient starts in the US market and expand its global footprint by an impressive 50%. To achieve these objectives, Senseonics will focus on product development, establishing strategic healthcare partnerships, and the international launch of the Eversense 365 system.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.